Evaluation of Solifenacin Succinate in the treatment of in patients whit mixed urinary incontinence

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231228060553N1

Enrollment

294

Registered

2024-10-15

Start date

2024-05-21

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mixed urinary incontinence. Other specified urinary incontinence

Interventions

Intervention 1: Intervention group: In the target group, the drug sulfinasin succinate (VSOL 5mg) is prescribed orally to the patient daily after breakfast for three months, and the patients treatment

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Willingness to participate in the plan Mixed urinary incontinence Taking medicine until the end of the treatment period

Exclusion criteria

Exclusion criteria: Unwillingness to participate in the plan Using other treatment methods along with sulifinacin succinate Failure to take medicine regularly and until the end of the course Positive PVR detected through ultrasound Prolapse STAG3,4 UTI Diabetes

Design outcomes

Primary

Measure	Time frame
Mixed urinary incontinence. Timepoint: Checking the effectiveness of the drug one and a half months and three months after the start of the study. Method of measurement: Physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNastaran Teymoorianfard

Shahid Beheshti University of Medical Sciences

na.teymoorianfard@gmail.com+98 21 2303 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026